In This Article:
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025.
Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development. With a proven track record in investment management gained over more than two decades, his experience in business development and capital deployment, together with his deep roots in the biotech and scientific communities, make him a valuable addition to the board of directors. Mr. Nodelman represents the seventh new director elected or appointed over the past two years as part of the company’s board renewal process.
Mr. Nodelman received a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University. He currently serves as a director of two other publicly-traded life science companies, Galapagos NV and AnaptysBio.
“As the largest current stockholder of Zymeworks, we at EcoR1 are aligned with the company’s mission and committed to its future success for patients, employees and stockholders,” said Oleg Nodelman. “I look forward to working closely with the board of directors and talented employees as we execute on our long-term strategy to realize the full potential of Zymeworks.”
“We are pleased to welcome Oleg to Zymeworks’ board of directors and believe his significant biotech sector experience will support our mission to develop transformative therapies for patients, while delivering lasting value to all our stockholders,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
“Oleg’s deep industry knowledge and experience make him an exceptional addition to the board of directors,” said Sue Mahony, Ph.D., MBA, lead independent director of Zymeworks. “As part of our board renewal process, we are confident that Oleg’s strategic insights will help drive the company’s growth and reinforce our dedication to addressing critical medical challenges for patients.”
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the United States. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251 planned for 2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.